<DOC>
	<DOCNO>NCT00422773</DOCNO>
	<brief_summary>The purpose study ass maximal tolerable dose assess safety chemotherapy-combination cetuximab , irinotecan , oxaliplatin 5-fluorouracil ( 5-FU ) /folinic acid ( FA ) first-line treatment metastatic colorectal cancer .</brief_summary>
	<brief_title>Safety Cetuximab Oxaliplatin/5-FU/FA/Irinotecan First-Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Dose escalation : The first three patient receive chemotherapy dose level 1 6 week ( first three cycle ) . The dose escalate next patient one dose level none three patient dose level experience dose-limiting toxicity ( DLT ) first six week . If one three patient DLT , additional three patient enrol dose level dose escalate additional patient experience DLT . Otherwise , dose escalation stop , last dose regard maximum tolerate dose ( MTD ) . An intra-individual dose escalation plan . Expanded cohort : The MTD cohort expand total 16 patient .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Diagnosis nonresectable , histologically confirm , epithelial growth factor receptor ( EGFR ) positive negative colorectal cancer WHO Performance status 0 1 Signed write informed consent ≥ 18 year age Effective contraception male female subject risk conception exists Adequate bone marrow function : neutrophil blood cell count ( NBC ) ≥ 1.5 x 10^9/L , platelet count ≥ 100 x 10^9/L , hemoglobin ≥ 5.96 mmol/L ( 10 g/dL ) Adequate liver renal function : bilirubin ≤ 1.5 x upper normal level ( UNL ) increase 25 % within last 4 week ; ASAT ALAT ≤ 5 x UNL ; serum creatinine ≤ 1.5 x UNL . Previous exposure epidermal growth factor receptortargeting therapy Previous chemotherapy colorectal cancer except adjuvant treatment progression disease document &gt; 6 month end adjuvant treatment 5FU combination radiotherapy rectal cancer Radiotherapy major abdominal thoracic surgery within last 4 week inclusion . Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy . Investigational agent participation clinical trial within 30 day start treatment study . Clinically relevant coronary disease myocardial infarction within 12 month study entry . Peripheral neuropathy &gt; CTC ( Common Toxicity Criteria ) grade I Inflammatory bowel disease Previous malignancy ( except colorectal cancer , history basal cell carcinoma skin preinvasive carcinoma cervix adequate treatment ) History severe psychiatric illness Drug alcohol abuse Known hypersensitivity reaction component study treatment Pregnancy ( absence confirm bhCG ( pregnancy ) test ) lactation period Brain metastasis and/or leptomeningeal disease ( know suspect ) Acute subacute intestinal occlusion history inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>phase I/II</keyword>
	<keyword>cetuximab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>5-FU</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>safety</keyword>
</DOC>